CN101415704A - 作为plk1抑制剂的4-苯基-噻唑-5-羧酸和4-苯基-噻唑-5-羧酸酰胺 - Google Patents

作为plk1抑制剂的4-苯基-噻唑-5-羧酸和4-苯基-噻唑-5-羧酸酰胺 Download PDF

Info

Publication number
CN101415704A
CN101415704A CNA2007800068055A CN200780006805A CN101415704A CN 101415704 A CN101415704 A CN 101415704A CN A2007800068055 A CNA2007800068055 A CN A2007800068055A CN 200780006805 A CN200780006805 A CN 200780006805A CN 101415704 A CN101415704 A CN 101415704A
Authority
CN
China
Prior art keywords
thiazole
carboxylic acid
phenyl
benzimidazol
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800068055A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·弗雷德里克·博伊兰
蔡建平
纳德尔·佛投赫
保罗·吉莱斯皮
罗伯特·阿兰·小古德诺
乐康
克里斯托夫·米舒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101415704A publication Critical patent/CN101415704A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNA2007800068055A 2006-02-27 2007-02-19 作为plk1抑制剂的4-苯基-噻唑-5-羧酸和4-苯基-噻唑-5-羧酸酰胺 Pending CN101415704A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77696406P 2006-02-27 2006-02-27
US60/776,964 2006-02-27

Publications (1)

Publication Number Publication Date
CN101415704A true CN101415704A (zh) 2009-04-22

Family

ID=38051896

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800068055A Pending CN101415704A (zh) 2006-02-27 2007-02-19 作为plk1抑制剂的4-苯基-噻唑-5-羧酸和4-苯基-噻唑-5-羧酸酰胺

Country Status (19)

Country Link
US (1) US7504513B2 (https=)
EP (1) EP1991543A1 (https=)
JP (1) JP2009528284A (https=)
KR (1) KR101060539B1 (https=)
CN (1) CN101415704A (https=)
AR (1) AR059621A1 (https=)
AU (1) AU2007217575A1 (https=)
BR (1) BRPI0710473A2 (https=)
CA (1) CA2642921A1 (https=)
CR (1) CR10206A (https=)
EC (1) ECSP088700A (https=)
IL (1) IL193481A0 (https=)
MA (1) MA30260B1 (https=)
MX (1) MX2008010884A (https=)
NO (1) NO20083708L (https=)
RU (1) RU2008138163A (https=)
TW (1) TW200745097A (https=)
WO (1) WO2007096315A1 (https=)
ZA (1) ZA200807074B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008149784A1 (ja) * 2007-06-08 2008-12-11 Nec Corporation 半導体集積回路及びフィルタ制御方法
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US8962614B2 (en) * 2008-04-17 2015-02-24 The Johns Hopkins University ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors
WO2010029327A1 (en) * 2008-09-10 2010-03-18 Datalase Ltd. Data storage medium
WO2010077295A1 (en) * 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Centre Substituted tricyclic heterocycles and uses to treat tumors and proliferative disorders
WO2010121675A2 (en) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322429A (en) * 1980-09-16 1982-03-30 Eli Lilly And Company Isoxazolylbenzamides as insecticides
US4818270A (en) * 1986-08-28 1989-04-04 Monsanto Company 2-(Heteroamino)-4,5-substituted-oxazole/thiazole compounds as herbicide antidotes, compositions and use
US6194447B1 (en) * 1998-07-02 2001-02-27 Neurosearch A/S Bis (benzimidazole) derivatives serving as potassium blocking agents
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
CA2515243A1 (en) 2002-02-22 2003-08-28 Klaus Strebhardt Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
US7183276B2 (en) * 2002-02-28 2007-02-27 Takeda Pharmaceutical Company Limited Azole compounds
WO2003072062A2 (en) 2002-02-28 2003-09-04 Temple University-Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
JP2003321460A (ja) * 2002-02-28 2003-11-11 Takeda Chem Ind Ltd アゾール化合物
US20060079503A1 (en) 2002-05-03 2006-04-13 Schering Aktiengesellschaft Thiazolidinones and the use therof as polo-like kinase inhibitors
US6906186B1 (en) 2002-07-30 2005-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of polo-like kinase expression
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US20050196808A1 (en) 2002-11-14 2005-09-08 Yaffe Michael B. Products and processes for modulating peptide-peptide binding domain interactions
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
JP3837670B2 (ja) 2002-12-12 2006-10-25 富士通株式会社 データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
JP2006522127A (ja) 2003-04-01 2006-09-28 スミスクライン ビーチャム コーポレーション イミダゾトリアジン化合物
EP1641780B1 (en) 2003-06-24 2008-11-12 Pfizer Products Incorporated Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
WO2005019193A2 (en) 2003-08-20 2005-03-03 Smithkline Beecham Corporation Phenylurea derivatives useful in the treatment of conditions mediated by polo-like kinases (plk)
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
DE10351744A1 (de) 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
EP1711496A4 (en) 2004-01-28 2009-02-11 Smithkline Beecham Corp THIAZOLE COMPOUNDS

Also Published As

Publication number Publication date
BRPI0710473A2 (pt) 2011-08-16
ECSP088700A (es) 2008-09-29
CR10206A (es) 2008-09-22
US7504513B2 (en) 2009-03-17
IL193481A0 (en) 2009-05-04
AU2007217575A1 (en) 2007-08-30
TW200745097A (en) 2007-12-16
MA30260B1 (fr) 2009-03-02
US20070203210A1 (en) 2007-08-30
ZA200807074B (en) 2009-10-28
NO20083708L (no) 2008-09-23
RU2008138163A (ru) 2010-04-10
EP1991543A1 (en) 2008-11-19
AR059621A1 (es) 2008-04-16
MX2008010884A (es) 2008-09-03
JP2009528284A (ja) 2009-08-06
WO2007096315A1 (en) 2007-08-30
KR20080090550A (ko) 2008-10-08
CA2642921A1 (en) 2007-08-30
KR101060539B1 (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
CN101415704A (zh) 作为plk1抑制剂的4-苯基-噻唑-5-羧酸和4-苯基-噻唑-5-羧酸酰胺
JP4805916B2 (ja) 化合物、組成物、および方法
EP2493862B1 (en) Imidazole derivatives as ido inhibitors
CN112778275B (zh) 金刚烷基prmt5抑制剂及其应用
CN101098872B (zh) 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
AU2002313410B2 (en) Hepatitis C virus polymerase inhibitors with a heterobicyclic structure
CN104003940B (zh) 2,4‑二氟‑5‑(酞嗪酮‑1‑甲基)‑苯甲酰哌嗪类化合物及其用途
CN101103026A (zh) 用于治疗病毒感染的吲哚衍生物
CN101155783B (zh) 吡唑类化合物
WO2005095419A1 (ja) チアゾロピリミジン誘導体
CN101835766B (zh) 作为腺苷a1受体拮抗体的化合物
WO2012034363A1 (zh) 作为hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
CN110049978A (zh) 作为选择性hdac1,2抑制剂的哌嗪衍生物
HUT75117A (en) Pyrrole derivatives
CN113166105B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN107879975A (zh) 组蛋白去乙酰化酶抑制剂及其应用
WO2012131501A1 (en) Substituted benzimidazole compounds as cot kinase inhibitors
US7714010B2 (en) Pyrrolobenzimidazolones and their use as anti-proliferative agents
RS59787B1 (sr) Novo heterociklično jedinjenje, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
CN114621194B (zh) 一种4-亚甲基-n-羟基苯甲酰胺类化合物及其应用
EP3749671A1 (en) [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives
WO2004099190A1 (en) Novel substituted benzimidazole derivatives
AU2020264679B2 (en) Selective ligands of human constitutive androstane receptor
JP2009514865A (ja) 有糸分裂キネシン阻害剤
US20240217969A1 (en) Substituted pyrrole carboxamides, process for their preparation and their use as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20090422

C20 Patent right or utility model deemed to be abandoned or is abandoned